MedTrace Logo

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

NCT04161014 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-10

No results posted yet for this study

Summary

Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis.

Subjects will be treated with Nintedanib 150mg twice daily for 3 years.

Conditions

  • Pneumoconiosis Coal
  • Asbestosis
  • Silicosis

Interventions

DRUG

Nintedanib 150 MG [Ofev]

Nintedanib 150mg twice daily for 3 years

Sponsors & Collaborators

Principal Investigators

  • Deborah Yates, A/Prof · Holdsworth House Medical Practice

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-09
Primary Completion
2024-12-31
Completion
2025-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161014 on ClinicalTrials.gov